Reference no: EM133964543

Question

A drug salesperson claims their screening test for disease "Z" adds 3 additional months to a patient's life. Before you invest money into the screening test you review the biomedical literature concerning the new screening test. After review of the literature, you determine that 85% of patients die within 5 years of being diagnosed with disease "Z" , irrespective of whether or not they were first diagnosed by the new screening test. You also note that disease "Z" actually has an average preclinical phase of 9 months. Which of the following is most likely true? A. You should have the new screening test completed during your yearly check-up because it will add 3 additional months to your life if you are diagnosed with disease "Z" B. The new screening test clearly adds 3 months of life to patients diagnosed with disease "Z"; however, you must evaluate cost-effectiveness before you invest in this product C. The drug salesperson's claim that the screening test adds 3 additional months of life is likely due to "Lead Time Bias".